Nabla vs Owkin

By valuation, Owkin is the larger company at $1B versus $180M — a 5.6x difference. Size can also be measured by team: Nabla employs 80 people while Owkin has 450 employees.

Owkin has raised more in total funding at $334M, compared to Nabla's $30M — a gap of $304M. Combined, the two companies have completed 4 known funding rounds.

Nabla holds the higher Awaira Score at 73/100, compared to Owkin's 69/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 4-point gap that reflects meaningful differences in scale or traction.

Nabla was founded by Alexandre Lebrun in 2018. Owkin was founded by Thomas Clozel in 2016. Visit each company's profile on Awaira for a full founder biography.

Nabla: Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows. The company has raised $30M in total funding and operates at Series B stage with a valuation of $200M. Nabla's core offering focuses on AI-powered clinical documentation tools designed to reduce administrative burden on healthcare providers. The platform leverages natural language processing and machine learning to automate medical note-taking, allowing physicians to spend more time with patients rather than on paperwork. The company targets hospitals, clinics, and healthcare systems across Europe, with particular strength in the French market. Nabla's technology integrates with existing electronic health record systems and clinical workflows. The company competes in the growing digital health and healthcare AI sector alongside players focused on clinical automation and documentation efficiency. Nabla's approach emphasizes practical integration into existing healthcare infrastructure rather than building standalone applications. The company has demonstrated traction in European healthcare markets where administrative burden on clinicians remains significant. Its Series B funding stage indicates successful product-market fit validation and positions Nabla for expanded market reach and product development in the healthcare AI space. Nabla addresses the specific pain point of clinical documentation burden through AI automation, allowing European healthcare providers to improve operational efficiency. Owkin: Owkin is a French AI healthcare company founded in 2016 that develops federated learning and privacy-preserving machine learning technologies for drug discovery and clinical research. The company operates a distributed AI platform enabling pharmaceutical companies, biotech firms, and research institutions to collaborate on data analysis without sharing sensitive patient information or proprietary datasets. Owkin's core technology utilizes federated learning, allowing multiple parties to train machine learning models collectively while maintaining data privacy and regulatory compliance, particularly under GDPR and HIPAA frameworks. The company has raised $334 million in total funding and achieved a $1.0 billion valuation, positioning it as a significant player in the intersection of AI, privacy-tech, and healthcare. Owkin operates in the Series B stage and serves pharmaceutical companies seeking to accelerate drug development through collaborative AI while preserving data confidentiality. The platform addresses a critical challenge in healthcare AI: enabling large-scale machine learning without centralizing sensitive medical data. Owkin's approach contrasts with traditional cloud-based analytics solutions by maintaining data sovereignty at source institutions. The company has established partnerships across the pharmaceutical and research sectors, though specific customer names and financial metrics remain Not disclosed. Its growth trajectory reflects expanding demand for privacy-preserving AI solutions in highly regulated healthcare markets. Owkin combines federated learning with healthcare applications, enabling collaborative AI research without compromising data privacy or regulatory compliance across distributed pharmaceutical ecosystems.

Owkin was founded first in 2016, giving it 2 years of additional market experience. Nabla was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Nabla has approximately 80 employees, while Owkin has approximately 450. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Nabla and Owkin are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.